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Received April 20, 2011; accepted May 31, 2011AbstractKawasaki disease (KD) is acute systemic vasculitis that occurs mainly in infants and children under 5 years of age. The etiology of KD
remains unknown. KD is liable to be complicated by coronary artery lesions (CALs), which develop in approximately 15e25% of untreated KD
children and in approximately 5% of KD children after intravenous immunoglobulin (IVIG) therapy. A single high dose of IVIG (2 g/kg) is the
gold standard therapy in the acute stage of KD. However, approximately 8e38% of children are unresponsive to initial IVIG treatment and at
increased risk for CAL development. Anti-inflammatory high doses of aspirin are recommended in conjunction with IVIG, but our study
demonstrated that there is no evidence of efficacy in preventing CAL development. The usefulness of steroids in initial therapy for KD or
treatment of IVIG-resistant patients is not well established. Other immunosuppressive therapies, including infliximab, have been used in the
treatment of refractory KD, but merit additional investigation. Subclinical atherosclerosis may develop early in KD patients, which makes early
initiation of therapy to improve chronic inflammation an important issue. Future multicenter studies may help to define the optimal management
of KD patients.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Kawasaki disease (KD), an acute systemic vasculitis more
prevalent in Asian races, occurs mainly in infants and children
under 5 years of age.1 This multisystem vasculitis is charac-
terized by prolonged fever, polymorphous skin rash, non-
purulent conjunctival injection, extremity changes, oral
mucosal changes, and cervical lymphadenopathy. KD is liable
to be complicated by coronary artery lesions (CALs), which
develop in approximately 15e25% of untreated KD children2e4
and in approximately 5% of KD children after intravenous
immunoglobulin (IVIG) therapy.5,6 The etiology of KD remains
unknown andmay be attributed to combined effects of infection,
immune response, and genetic susceptibility.1 The annual* Corresponding author. Dr. Kai-Sheng Hsieh, Department of Pediatrics,
Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung
813, Taiwan, ROC.
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1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.09.001incidence of KD in Taiwan is estimated to be 69/100,000 chil-
dren, the third highest in the world after Japan and Korea.7e9
Many researchers have made great efforts to unravel the
mystery of the disease. Evidence on the treatment of KD from
randomized clinical trials is well established.5 The present
review article covers previous important publications with
a special focus on the treatment of KD.
2. IVIG
Treatment with a single high dose (2 g/kg) of IVIG is
effective in reducing the incidence of CALs.6,10,11 A study by
Newburger et al11 contributed greatly in this regard, and
a single high dose of IVIG is the gold standard therapy in the
acute stage of KD. The mechanism of IVIG in reducing
inflammation in KD is not clearly understood. Five possible
mechanisms include Fc receptor blockade, neutralization of
the causative agents or a toxin produced by an infectious
agent, an immunomodulating effect, induction of suppressorhinese Medical Association. All rights reserved.
482 K.-P. Weng et al. / Journal of the Chinese Medical Association 74 (2011) 481e484activity, and modulation of the production of cytokines and
cytokine antagonists.12 Takatsuki et al showed that IVIG
reduced the activity of oxidative stress,13 which provokes
vasculitis in KD. Using a murine model of KD, Lau et al
demonstrated that at therapeutic concentrations, IVIG effec-
tively reduced the immune response leading to tumor necrosis
factor (TNF) expression (a prerequisite for coronary arter-
itis).14 However, 7.8e38.3% of children are unresponsive to
initial IVIG treatment and at increased risk for CAL devel-
opment.15e20 Additional IVIG,15 steroid,21 infliximab,22 or
other treatments have been used for IVIG-resistant patients,
but controversy remains as regards alternative treatments.
Additional treatments after initial IVIG treatment failure may
not be effective for reducing fever or preventing coronary
artery injury.15,23 For IVIG-resistant patients, earlier and more
effective primary therapy might not be emphasized enough for
reducing the risk of CALs. Potentially effective initial treat-
ments for high-risk patients might be IVIG plus corticosteroids
or another new agent, such as infliximab.24,25 Additional
studies of KD pathogenesis are warranted to determine the role
of these therapies for IVIG nonresponders.
3. Aspirin
Anti-inflammatory doses of aspirin are recommended in
conjunction with IVIG, but controversy remains regarding
anti-inflammatory doses of aspirin.1 In North America, high-
dose (80e100 mg/kg per day) aspirin is most widely used
during the acute phase.26 In Japan, concern about hepatic
toxicity has led to the use of moderate-dose (30e50 mg/kg per
day) aspirin as a recommended standard therapy in the acute
phase.27 In Taiwan, IVIG with concomitant aspirin is used
during acute-stage KD in most hospitals except Kaohsiung
Veterans General Hospital. The results of our previous study
indicate that treatment without aspirin in acute-stage KD had
no effect on the response rate of IVIG therapy, duration of
fever, or CAL incidence.6 Using a murine model of KD, Lau
et al showed that at therapeutic concentrations, IVIG effec-
tively reduced the immune response leading to TNF-a, but
pharmacologic doses of salicylate enhanced its production.14
This finding may partly support our treatment without
aspirin in acute-stage KD. We suggest that it is unnecessary to
expose children to high- or medium-dose aspirin therapy in
acute KD when the available data show no appreciable benefit
in preventing the failure of IVIG therapy or CAL formation or
in shortening fever duration.
4. Steroids
Although corticosteroids are the treatment of choice in
other forms of vasculitis, the usefulness of steroids in treat-
ment of KD is not well established. Corticosteroids were used
as the initial therapy for KD long before the first report of
IVIG efficacy by Furusho et al.28 An early study by Kato
et al29 suggested that steroids exerted a negative effect when
used as the initial therapy for KD, but some recent studies
have shown possible benefit. Okada et al reported thatcorticosteroid therapy combined with IVIG as the initial
treatment rapidly ameliorated symptoms by reducing cytokine
levels in children with KD.30 Okada et al also showed that
methylprednisolone and IVIG was effective and safe as
a primary treatment for high-risk KD patients.24 However,
Newburger et al demonstrated that their data do not provide
support for the addition of a single pulsed dose of intravenous
methylprednisolone to IVIG for routine primary treatment of
children with KD.31 Further multicenter controlled trials are
required to elucidate the role of methylprednisolone in initial
therapy for KD or treatment of IVIG-resistant patients.
5. Other treatments
A new class of therapies directed against specific cytokines
has expanded treatment for KD. Infliximab is a monoclonal
antibody to TNF-a and has been effective in the treatment of
patients with refractory KD.32,33 Treatment with infliximab
might also be an initial therapy for high-risk KD patients.25
Our previous study showed an effect of IL-1B poly-
morphism on the association with IVIG resistance in Taiwa-
nese children with KD,34 which suggests the potential
usefulness of monoclonal antibodies to IL-1, such as anakinra,
for IVIG-resistant patients.35 Other immunosuppressive ther-
apies, including cyclophosphamide,36 methotrexate,37 and
plasma exchange,38 have been used in the treatment of
refractory KD. No definite conclusions can be reached from
these rare individual cases. Prospective clinical trials are
warranted to determine the role of these therapies.
6. Statins
Therapeutic regimens in the chronic stage of KD depend on
the severity of coronary artery involvement and include anti-
platelet therapy with aspirin, with or without dipyridamole or
clopidogrel, anticoagulant therapy with warfarin or low-
molecular-weight heparin.1 Ongoing low-grade inflammation
and endothelial dysfunction persist in patients with a history of
KD.39 Some studies also demonstrated that subclinical athero-
sclerosis develops early in KD patients,40,41 which makes early
initiation of therapy to improve chronic inflammation an
important issue. Statins are well-known lipid-lowering agents,
but have so-called pleiotropic, cholesterol-independent effects
that are believed to include anti-proliferative, anti-inflamma-
tory, and antioxidant actions; they also upregulate eNOS
activity.42e44 Our pilot study has shown that statin therapy
seems to significantly improve chronic vascular inflammation
and endothelial dysfunction in children with coronary arterial
abnormality in the chronic stage of KD.45 A recent animal study
also demonstrated that atorvastatin can inhibit critical patho-
genic steps in the development of coronary artery damage in
KD.46 Further study is needed to determine the safety and
efficacy of statins in children with KD.
In conclusion, high-dose IVIG in the acute phase of KD is
the accepted treatment guideline. Anti-inflammatory high
doses of aspirin are recommended in conjunction with IVIG,
but the efficacy of aspirin may be limited to its anticoagulant
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Additional treatments after initial IVIG treatment failure,
including corticosteriod therapy, are controversial. Manage-
ment in the chronic stage of KD, especially for patients
without evidence of CALs, is still an issue under debate.
Future multicenter studies may help to define the optimal
management for KD patients.Acknowledgments
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